Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

Do doctors understand the individualisation of treatments?

The individualisation of drug treatments to support patients to self-manage their conditions is a concept that sits at the heart of policy, but a recent study in BMJ Open shows that there is no concrete definition of the term and consequently no cohe...

Cenix Bioscience and Debiopharm collaborate to identify predictive biomarkers

Cenix BioScience, a specialist in preclinical contract research and technology development in the field of RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group (Debiopharm), a Switzerland-headquartered global biopharmaceutical gro...

MedImmune and KineMed study protein dynamics related to neurodegenerative diseases

MedImmune and KineMed Inc have formed an agreement to study how a monoclonal antibody affects the dynamics of the cellular prion protein (PrPc), which is known to have altered conformation and function in several neurodegenerative conditions includin...

Parents Underestimate Influence Over Teens' Substance Abuse: Survey

FRIDAY, May 24 (HealthDay News) -- About one in five parents think they have little control over whether their teens take up smoking, drinking or illicit drug use, a new U.S. government survey finds. That's too bad, say experts at the Substance Abus...

Ignyta acquires Actagene Oncology

US company Ignyta, Inc has acquired Actagene Oncology, Inc, a San Diego based biotechnology company founded in February 2013 that was developing personalised medicines for cancer indications based on genome mining and sequencing. Ignyta says the acqu...

Astellas seeks Japan approval of Xtandi

Following a go-ahead for marketing approval in the EU last month, Medivation's novel prostate cancer drug enzalutamide has been filed for approval in Japan by ex-US global licensee Astellas. The once-daily oral androgen receptor.....

A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013

ByTech Guru:With a potential U.S. market for Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) patients of almost $1bb, based on 5mm CKD patients above age 65, of whom ~50% are in stage 3-5, there is ample opportunity for a few under-appreciated stories focusing on this market to see real traction as we head into 2H/13. I've highlighted a few of the more notable playe...

RPT-Novo sees US obesity drug launch end 2014/start of 2015-CSO

COPENHAGEN, May 24 (Reuters) - Denmark's Novo Nordisk said it expects to launch its liraglutide obesity treatment in the Unites States at the end of next year or start of 2015 after Phase III results late on Thursday confirmed weight loss in patients...

Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology

Quincy Bioscience announces publication of safety assessment study of apoaequorin in the July issue of Food and Chemical Toxicology. Apoaequorin is used in dietary supplements and as a food ingredient to improve mild memory loss associated with aging. Madison, WI (PRWEB) May 24, 2013 Quincy Bioscience, a leading research company committed to the discovery and development of calcium-binding protei...

Novo sees US obesity drug launch end 2014/start of 2015-CSO

COPENHAGEN, May 24 (Reuters) - Denmark's Novo Nordisk said it expects to launch its liraglutide obesity treatment in the Unites States at the end of next year or start of 2015 after Phase III results late on Thursday confirmed weight loss in patients...

FDA Drug Safety Communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR

The U.S. Food and Drug Administration (FDA) is notifying the public that FDA has approved label changes specifying new dosing recommendations for zolpidem products (Ambien, Ambien CR, and Edluar), which are widely prescribed sleep medications.

It Takes A Global Village to End MS

NEW YORK, May 24, 2013 /PRNewswire-USNewswire/ -- Multiple sclerosis is a life altering disease that affects each person in a unique and different way.   More than 2.1 million people worldwide live with MS, which is why demonstrating the power and importance of the global MS movement is critical on World MS Day -- May 29. (Logo: http://photos.prnewswire.com/prnh/20090302/DC77093LOGO)...

Research: Anti-cancer drug tested as possible treatment for Alzheimer's disease proved ineffective

An anti-cancer drug about to be tested in a clinical trial by a biomedical company in Ohio as a possible treatment for Alzheimer's disease has failed to work with the same type of brain plaques that plague Alzheimer's patients, according to results o...

Servier, miRagen to add third cardiovascular target under strategic alliance

Servier and miRagen Therapeutics have announced the selection of a third target under the agreement aimed at advancing the research and commercialization of microRNA-based drug candidates against cardiovascular diseases.

Christian Drug Rehab Treatment Center Announces First Annual Scavenger Hunt

Recovery Associates, a Christian drug and alcohol rehab , will be hosting its First Annual Scavenger Hunt June 1st. The event is being organized by their new Alumni Director. (PRWEB) May 24, 2013 For a lot of addicts in early sobriety, socializing without drugs and alcohol is a whole new experience. They have become so accustom to relying on substances to form friendships that meeting new people...

Adderall Addiction Treatment and Adderall Drug Rehab Announced

Adderall addiction treatment and drug rehab announced by Recovery Associates, offering treatment for those addicted to the powerful study drug. Recovery Associates helps people get their lives together after becoming addicted to Adderall. WEST PALM BEACH, Fla. (PRWEB) May 24, 2013 Recovery Associates, through its multiple therapeutic tracks, is placing an emphasis upon Adderall addiction treatme...

Destination Hope Women's Program Discusses the Importance of Dual Diagnosis Treatment During Mental Health Awareness Month

South Florida Substance Abuse Treatment Center for Women looks beyond the symptoms of addiction to successfully treat women battling substance addiction. Fort Lauderdale, FL (PRWEB) May 24, 2013 Destination Hope: The Women’s Program, a nationally recognized gender specific substance abuse treatment and alcohol rehab for women facility in Fort Lauderdale, Florida, celebrates Mental Health Awaren...

HPV Infects up to 65% of Pregnant Women; polyDNA Recommends Gene-Eden-VIR as a Preparation for Pregnancy

In a new study it was revealed that up to 72% of new mothers with HPV transmit the virus to their newborns. polyDNA recommends Gene-Eden-VIR to help the immune system clear the HPV virus as a preparation for pregnancy. Rochester, NY (PRWEB) May 24, 2013 “Vertical transmission of HPV is associated with vaginal delivery.” This is according to the European Journal of Obstetrics, Gynecology, and...

SSRIs (incl. Paxil) May Increase Risk of Complications after Surgery: Now, AttorneyOne Can Provide Advice for Legal Counsel

As Time published on April 30, a new study revealed that selective serotonin reuptake inhibitors (SSRIs), including Paxil, are linked to higher risk of complications after surgery. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Paxil side effects. Sa...

BioInvent Recruits Michael Oredsson as New CEO

BioInvent International AB (STO: BINV) announces today that the Company's Board of Directors has appointed Michael Oredsson as new President and CEO. He will take office within six months. Michael Oredsson has a degree in International Business Administration and has for many years held senior executive positions in the pharmaceutical and biotech...

FDA clears Omeros' IND for OMS824 in Huntington's disease

The US Food and Drug Administration (FDA) has cleared Omeros' investigational new drug application (IND) for OMS824 in Huntington's disease.

Amarin Stays Rangebound, Prescriptions Stagnate

By Brian L. Wilson:Amarin Corporation (NASDAQ: AMRN) has been struggling a lot lately as retail channel prescription data for its EPA capsule Vascepa imply that the drug is starting to slow down its momentum in the MARINE indication (hypertriglyceridemia patients with >500 mg/dL). While the company has seen significant progress since the launch of the drug in January, it is still not causing an...

FDA to have stringent rules for medical apps

US Food and Drug Administration intends to have tighter rules for apps that allow diagnose or treat medical conditions, similar to the 2011 proposal urging for quality standards for ultrasound machines, heart stents, and several other medical equipme...

FDA plans to have stringent rules for medical apps

US Food and Drug Administration intends to have tighter rules for apps that allow to diagnose or treat medical conditions, similar to the 2011 proposal urging for quality standards for ultrasound machines, heart stents, and several other medical equi...

Elan prices $850 million senior notes

DUBLIN, May 24 (Reuters) - Irish drug firm Elan will issue $850 million worth of senior notes at par, the company said on Friday.